The TK2 gene encodes Thymidine Kinase 2, a mitochondrial matrix enzyme that catalyzes the phosphorylation of thymidine and deoxycytidine to their monophosphate forms as part of the mitochondrial nucleotide salvage pathway. TK2 is essential for maintaining mitochondrial DNA (mtDNA) levels through its role in providing deoxynucleoside triphosphates (dNTPs) for mtDNA replication. Mutations in TK2 cause mitochondrial DNA depletion syndrome (MTDPS), a severe disorder characterized by progressive muscle weakness, respiratory failure, and often early childhood mortality.
Mitochondrial DNA depletion syndrome (MTDPS) represents a group of autosomal recessive disorders characterized by a severe reduction in the copy number of mitochondrial DNA in affected tissues. Unlike nuclear DNA mutations that directly affect mitochondrial proteins, MTDPS results from impaired maintenance and replication of mtDNA. TK2 mutations are among the most common causes of MTDPS and primarily affect skeletal muscle, leading to progressive myopathy.
TK2 is one of two thymidine kinases in human cells: TK1 is cytosolic and participates in the salvage pathway for nuclear DNA replication, while TK2 is mitochondrial and provides dNTPs for mtDNA replication. This compartmentalization is critical because mtDNA replication occurs in the mitochondrial matrix and requires a dedicated supply of dNTPs that cannot be efficiently imported from the cytosol.
The discovery that TK2 mutations cause MTDPS highlighted the importance of the mitochondrial nucleotide salvage pathway in maintaining mtDNA copy number. Patients with TK2 deficiency present with progressive mitochondrial myopathy, often in infancy or early childhood, with symptoms including muscle weakness, hypotonia, and respiratory failure. The severity of the phenotype reflects the essential nature of mtDNA for mitochondrial function, particularly in high-energy tissues like skeletal muscle.
TK2 catalyzes the phosphorylation of thymidine (dT) and deoxycytidine (dC) to their respective monophosphates (dTMP and dCMP) using ATP as the phosphate donor:
dT + ATP → dTMP + ADP
dC + ATP → dCMP + ADP
This reaction is the first step in the mitochondrial nucleotide salvage pathway. The resulting monophosphates are subsequently phosphorylated by other mitochondrial kinases to produce the dNTPs required for mtDNA replication.
TK2 exhibits broad substrate specificity, accepting both thymidine and deoxycytidine as substrates. This dual specificity is important because mtDNA contains both thymidine and cytidine in its composition.
TK2 is synthesized in the cytoplasm and imported into the mitochondrial matrix through a targeting sequence at its N-terminus. The mitochondrial import machinery recognizes this presequence and translocates TK2 across the inner mitochondrial membrane into the matrix, where it remains as a soluble enzyme.
The mitochondrial localization of TK2 is essential for its function because mtDNA replication occurs within the mitochondrial matrix and requires locally synthesized dNTPs. The mitochondrial membrane is impermeable to nucleotides, necessitating dedicated synthesis within the organelle.
The mitochondrial nucleotide salvage pathway provides dNTPs for mtDNA replication through a series of enzymatic reactions:
This pathway contrasts with the de novo synthesis pathway, which operates in the cytosol and is not directly available for mtDNA replication due to membrane barriers. The salvage pathway is particularly important in non-dividing cells like neurons and muscle cells, where de novo synthesis is limited.
TK2 activity directly influences mtDNA copy number. Adequate TK2 activity ensures sufficient dNTP supply for mtDNA replication, maintaining normal mtDNA levels. Conversely, reduced TK2 activity leads to insufficient dNTP supply, causing progressive mtDNA depletion.
The regulation of TK2 expression and activity is linked to cellular energy status and mitochondrial biogenesis. Under conditions of increased mitochondrial demand, TK2 expression may be upregulated to support mtDNA replication for new mitochondria.
TK2 mutations are a well-established cause of MTDPS, typically presenting as mitochondrial myopathy with childhood onset. The clinical spectrum includes:
Progressive Muscle Weakness: The hallmark symptom is progressive weakness of axial and limb muscles, often beginning in infancy or early childhood. Weakness is typically symmetric and affects proximal muscles more than distal.
Hypotonia: Reduced muscle tone is common, contributing to the "floppy infant" presentation in severe cases.
Respiratory Failure: Involvement of respiratory muscles can lead to respiratory insufficiency and failure, which is often the cause of mortality in severe cases.
Feeding Difficulties: Bulbar dysfunction can cause feeding difficulties and failure to thrive.
Exercise Intolerance: Affected individuals often have profound exercise intolerance due to impaired mitochondrial energy production.
Several recurrent TK2 mutations have been identified in patients with MTDPS:
Genotype-phenotype correlations exist, with some mutations (often missense) allowing residual enzyme activity and milder disease, while nonsense/frameshift mutations cause severe deficiency and early-onset disease.
Some patients with TK2 mutations present with mitochondrial myopathy featuring external ophthalmoplegia (limitation of eye movements). This phenotype overlaps with other mitochondrial myopathies like progressive external ophthalmoplegia (PEO).
Understanding TK2 function has led to therapeutic approaches for TK2-related MTDPS:
Nucleotide Supplementation: Oral supplementation with deoxyribonucleosides has shown promise in preclinical models and is being evaluated in clinical trials.
Gene Therapy: Approaches to deliver functional TK2 to affected tissues are under development.
Mitochondrial Biogenesis Stimulators: Agents that enhance mitochondrial biogenesis may help compensate for reduced mtDNA copy number.
While TK2-related MTDPS primarily affects skeletal muscle, the gene is expressed in various tissues including the brain:
The brainstem, which controls vital functions including respiration, expresses TK2. Brainstem involvement may contribute to the respiratory failure observed in severe cases.
Cerebellar expression of TK2 suggests a role in maintaining cerebellar mitochondrial function. Cerebellar dysfunction may contribute to ataxia in some patients.
Motor neurons in the spinal cord express TK2, which may be relevant to the muscle weakness observed in TK2 deficiency.
Mitochondrial DNA replication requires a dedicated set of enzymes including the mtDNA polymerase (POLG), the mtDNA helicase (TWNK), and the mitochondrial single-stranded DNA binding protein (SSBP1). These enzymes require a supply of dNTPs, which TK2 helps provide through the salvage pathway.
TK2 deficiency leads to imbalanced mitochondrial dNTP pools, with particular depletion of thymidine and deoxycytidine triphosphates. This imbalance affects the fidelity and efficiency of mtDNA replication.
mtDNA depletion leads to impaired oxidative phosphorylation, ATP deficiency, and ultimately cell death through apoptosis. The selective vulnerability of skeletal muscle reflects the high energy demands of this tissue.
Current therapeutic approaches for TK2-related MTDPS include:
Deoxyribonucleoside Therapy: Oral supplementation with dAMP, dTMP, dGMP, and dCMP has shown promise in animal models and early human studies.
CoQ10 Supplementation: Ubiquinone supplementation may help improve mitochondrial function in some patients.
Exercise Mimetics: Agents that stimulate mitochondrial biogenesis (such as bezafibrate) are being evaluated.
Gene Therapy: Adeno-associated virus (AAV) vectors carrying functional TK2 are in development.